Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001246766 | SCV001420148 | pathogenic | Renal carnitine transport defect | 2025-01-27 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg336*) in the SLC22A5 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC22A5 are known to be pathogenic (PMID: 9916797). This variant is present in population databases (rs754008420, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with SLC22A5-related conditions. ClinVar contains an entry for this variant (Variation ID: 971074). For these reasons, this variant has been classified as Pathogenic. |
Ce |
RCV002512148 | SCV002821315 | pathogenic | not provided | 2022-12-01 | criteria provided, single submitter | clinical testing | SLC22A5: PVS1, PM2 |
Revvity Omics, |
RCV001246766 | SCV003816419 | likely pathogenic | Renal carnitine transport defect | 2022-04-27 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001246766 | SCV003922886 | likely pathogenic | Renal carnitine transport defect | 2023-03-23 | criteria provided, single submitter | clinical testing | Variant summary: SLC22A5 c.1006C>T (p.Arg336X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 8e-06 in 251462 control chromosomes (gnomAD). c.1006C>T has been reported in the literature in a compound heterozygous individual affected with Systemic Primary Carnitine Deficiency (Louis_2023). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014, and classified the variant as pathogenic (n=2) or likely pathogenic (n=1). Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Baylor Genetics | RCV001246766 | SCV004203570 | likely pathogenic | Renal carnitine transport defect | 2024-02-07 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001246766 | SCV005669222 | pathogenic | Renal carnitine transport defect | 2024-03-20 | criteria provided, single submitter | clinical testing |